Dingdang Health Technology Group Ltd. (HK:9886)
:9886
Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$1.08
-HK$0.02(-3.23%)
At close: 4:00 PM EST
HK$1.08
-HK$0.02(-3.23%)
Day’s Range― - ―
52-Week RangeHK$0.46 - HK$1.37
Previous CloseN/A
Volume431.00K
Average Volume (3M)4.91M
Market Cap
HK$1.05B
Enterprise ValueHK$721.01M
Total Cash (Recent Filing)HK$1.36B
Total Debt (Recent Filing)HK$263.13M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,254,649,400
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$6.85B
Bulls Say, Bears Say
Bulls Say
O2O Pharmacy Platform And Delivery NetworkDingdang’s O2O model combines digital ordering with a physical pharmacy and delivery network, creating a durable fulfilment advantage for frequent, time-sensitive healthcare purchases. This omnichannel setup supports repeat usage, higher service stickiness and local logistics scale that persist beyond short-term cycles.
Sharp Revenue Rebound And Improving MarginsA 70% revenue rebound alongside rising gross margin indicates structural recovery in demand, better mix or pricing power, and improved unit economics. If sustained, these trends support moving toward consistent profitability by improving contribution per sale and reducing reliance on promotional discounts or unsustainable subsidies.
Positive Cash Generation And Manageable LeverageTurning to positive operating and free cash flow with low debt-to-equity improves financial flexibility and funds reinvestment without heavy external financing. Durable cash generation, combined with modest leverage, strengthens the company’s ability to invest in logistics, maintain operations and pursue growth initiatives over the medium term.
Bears Say
Net Losses Remain (profitability Not Yet Sustained)Despite marked improvement, the company remains slightly unprofitable at the net level. Continued negative net income means equity returns are still negative and limits internal capital for expansion or shareholder returns. Sustained profitability is required to fully de-risk the business model and validate the recovery.
Cash-flow Volatility And Durability ConcernsThe recent positive cash flows may reflect working-capital timing or one-off effects given prior multi-year negative cash generation. This volatility raises concern about the durability of cash conversion; if cash flow reverts, funding for growth or debt servicing could become constrained without external financing.
Historical Balance-sheet Stress And Negative ROEPast episodes of negative equity and high leverage highlight execution risk and leave legacy scars on financing flexibility. Persistently negative returns on equity through 2025 indicate the company has not yet generated consistent shareholder value, which can limit strategic options and investor confidence over the medium term.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.46 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$1.05B.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 73 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,254,649,400 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-2.95%
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―
Options Prices
Currently, No data available
---